Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Food Effect of ABBV-722 Tablet in Healthy Adults
NCT07361367Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABBV-722 (3 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Cmax and 5 more. Started Jan 2026; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT07361367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361367.